pam,
Thus the creation of new markets, like non-motor and nondopaminergic, which isn't a bad thing if it produces something. Of course that's just an opinion and a cynical one for sure.
My question is.....what evidence are all these changes based on?
Merck [dispensor of sinemet in europe] is partnering with Addex on a new market of drugs and delivery which is non-dopaminergic. I hope it works. i would like to trust it, but things change so quickly...companies are sold, etc etc.......
http://www.addexpharma.com/press-rel...-merck-co-inc/
paula
Quote:
Originally Posted by pkell
But I'm still having trouble understanding what the motive of the drug company could be. With as many baby-boomers as there are, why would they want to reduce the number of consuming units by eliminating the older (more advanced) ones?
If money is their motive, (and that's hardly a tough sell) I cannot understand how their financial gain is boosted by reducing the pool of consumers.
?????
|